Login to Your Account



CV Therapeutics Gets $70M Up Front in Ex-U.S. Ranexa Deal

By Trista Morrison


Monday, September 15, 2008
While U.S. label expansion efforts continue, CV Therapeutics Inc. granted ex-U.S. marketing rights for angina drug Ranexa (ranolazine prolonged-release tablets) to Menarini Group, of Florence, Italy. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription